Meta-analysis of programmed cell death 1 polymorphisms with systemic lupus erythematosus risk

Oncotarget. 2017 May 30;8(22):36885-36897. doi: 10.18632/oncotarget.16378.

Abstract

The association of polymorphisms in programmed cell death 1 (PDCD1) gene with systemic lupus erythematosus (SLE) risk is inconsistent across different studies. This meta-analysis is aimed to provide reliable evidence to the association of five common PDCD1 polymorphisms (PD1.1, PD1.2, PD1.3, PD1.5 and PD1.6) with SLE risk. A total of 28 studies with 4,344 SLE cases and 5,474 healthy controls were included in this meta-analysis. PD1.3 polymorphism was significantly associated with SLE in the overall population (A vs. G: OR = 1.35, 95% CI = 1.12-1.63; GA vs.GG: OR = 1.41, 95% CI = 1.12-1.76; AA+GA vs. GG: OR = 1.41, 95% CI = 1.13-1.7). In the stratified analyses based on ethnicity, we found a significant association in Caucasians and in Mexicans. In the subgroup analyses by gender, a significant association was found between PD1.3 polymorphism and SLE risk in males. The results also suggested an association between the PD1.6 polymorphism and decreased SLE risk (A vs. G: OR = 0.84, 95% CI = 0.73-0.96). Our meta-analysis revealed that PD1.3 polymorphism may increase the susceptibility to SLE, particularly in Caucasians, while PD1.6 may be a protective factor to SLE.

Keywords: PDCD1; SLE; meta-analysis; polymorphism; risk.

Publication types

  • Meta-Analysis
  • Review

MeSH terms

  • Alleles
  • Genetic Association Studies*
  • Genetic Predisposition to Disease*
  • Genotype
  • Humans
  • Lupus Erythematosus, Systemic / genetics*
  • Odds Ratio
  • Polymorphism, Single Nucleotide*
  • Programmed Cell Death 1 Receptor / genetics*
  • Publication Bias
  • Risk

Substances

  • Programmed Cell Death 1 Receptor